about
Disruption of ClC-3, a chloride channel expressed on synaptic vesicles, leads to a loss of the hippocampusPeptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkersInvolvement of NMDA receptors in alcohol-mediated behavior: mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanolNaturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.Alpha-helical-corticotropin-releasing hormone reverses anxiogenic effects of C-type natriuretic peptide in rats.Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment.Suicide attempts with mirtazapine overdose without complications.Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping studyMicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s DiseasePharmacological treatment of non-Alzheimer dementias.Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response.Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease.Use of proteomic methods in the analysis of human body fluids in Alzheimer research.A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease.Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network.The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types.Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.Augmented stress-induced alcohol drinking and withdrawal in mice lacking functional natriuretic peptide-A receptors.Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.Leptin: a modulator of alcohol craving?Leptin as a possible modulator of craving for alcohol.Free-choice alcohol consumption in mice after application of the appetite regulating peptide leptin.Activation of guanylate cyclase by natriuretic peptides in mouse pituitary AtT20 cells is influenced by phosphorylation of ANP.Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of cholecystokinin tetrapeptide in healthy men.Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.Alcohol intake, tumour necrosis factor-alpha, leptin and craving: factors of a possibly vicious circle?Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency?Alcohol self-administration, craving and HPA-axis activity: an intriguing relationship.The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.[Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations].Adjunctive use of reboxetine in schizophrenia.Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
P50
Q24290842-0FA13A24-A619-4241-8594-9266F5A6829EQ28477629-9E411730-F6C6-4E2C-A7C0-C0A087F233CFQ28585104-38881904-48A4-40DE-88F5-577376A01C55Q30430034-B96F6BD4-797A-4652-AD8A-B5D9971AD0A2Q31004962-492C2A9D-B742-447C-9751-F6637A10D9A9Q32062311-A3866747-5A70-4695-9320-7CB2D2103CC5Q33895227-3AB43F21-CA84-461C-A0D6-85B26F70CFB4Q34479125-DD5B2D02-693B-4F05-9D2D-27FD64CDE47DQ35012646-2108A2C6-EB25-41B9-9922-1D5F45953911Q35610026-20BA7DDD-2311-4694-BAC6-388A58270B58Q35629123-181DEA31-07F1-4C07-8793-372F5D0D530DQ36609184-F9DB32CF-97CE-44D1-B196-5839769DF9CAQ36813361-DDCB8E57-3E85-41A1-9BC4-2FFA86BD501CQ37241399-A0A1331F-313F-4138-A7B0-4EBA9D054803Q38060574-1988A948-897A-4BB9-A318-098C40674A13Q38392720-32A3D5E4-9767-4F57-A7B1-EE2839ACBD96Q39990508-F699A199-402B-4779-A99A-9F1C61F44E53Q40410694-E294A6F8-572B-4F92-82F8-612B0F56BB34Q42250827-C8BC476B-FE51-49F5-A65E-A61F3307CA30Q42374123-7DE4DC2E-A48F-4A5C-8820-495376C756AFQ43017632-F6D06670-FE6E-4D8C-85D3-D918BE81A7C3Q43069783-61816434-2C9B-465E-B96D-548BE44960EAQ43261463-833416F1-5D31-4559-B461-2EB556354444Q43570640-454B09B1-061B-41C1-B0D4-6EB36452D77FQ43593941-0551CFDA-5ABF-41A7-A105-4CE38F066ADDQ43601381-F2F8A84C-27BE-4F32-98E9-1215A2BE60D1Q43616577-C4E97493-A7C9-4603-B3FF-DB697FC2FB15Q43713013-9F5789F0-6428-40E4-8D10-12DA20FE8E3FQ43832859-62BFF787-5C44-4BE9-8AD7-BFF677F9641EQ43990766-3D9302D0-CAA2-4B62-8F2C-2DDFEB276E35Q44054946-EBE2C723-123D-41FB-9F16-811C08B1E471Q44097985-D86AF387-275F-4637-A5C1-AE6495A7BF54Q44196931-321F6989-CC65-4A41-B127-0777C33E83CDQ44530572-01DE343E-55B5-4413-828B-575F073CF609Q44589093-5C4A44AB-F1C3-4932-9FA7-4FFEC105D83FQ44846425-2180C5B5-CE58-4C7A-B00F-A41EF90EC65EQ44910834-E7D4F455-C877-4FCF-8EAF-1EFE5F0FCFA6Q44977945-75B8EEB6-859B-4214-966E-8C30E7138240Q45055718-554E4743-99CA-4C8E-9EF5-00AF75907EC0Q45176708-E77DFE39-D845-44C4-9874-1A66DA64C444
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Holger Jahn
@ast
Holger Jahn
@en
Holger Jahn
@es
Holger Jahn
@nl
Holger Jahn
@sl
type
label
Holger Jahn
@ast
Holger Jahn
@en
Holger Jahn
@es
Holger Jahn
@nl
Holger Jahn
@sl
prefLabel
Holger Jahn
@ast
Holger Jahn
@en
Holger Jahn
@es
Holger Jahn
@nl
Holger Jahn
@sl
P214
P1053
A-9255-2008
P106
P21
P214
P31
P3829
P496
0000-0003-3607-7651
P734
P735
P7859
viaf-292218984